Turn Therapeutics (NASDAQ:TTRX) Upgraded to Hold at WBB Securities

Turn Therapeutics (NASDAQ:TTRX) was upgraded by WBB Securities from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday, Marketbeat reports. The brokerage presently has a $10.00 target price on the stock. WBB Securities‘s price objective suggests a potential downside of 4.03% from the company’s current price.

TTRX has been the topic of a number of other reports. Wall Street Zen lowered Turn Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, October 18th. Lucid Cap Mkts raised Turn Therapeutics to a “strong-buy” rating in a research report on Thursday, September 24th. LADENBURG THALM/SH SH upgraded Turn Therapeutics to a “strong-buy” rating in a research note on Monday, July 20th. Zacks Research raised shares of Turn Therapeutics to a “hold” rating in a report on Tuesday, July 21st. Finally, Weiss Ratings lowered shares of Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 18th. Two analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $9.00.

Turn Therapeutics Stock Down 1.8%

Turn Therapeutics stock traded down $0.19 during midday trading on Friday, hitting $10.42. 98,415 shares of the stock were exchanged, compared to its average volume of 67,367. Turn Therapeutics has a 52-week low of $2.57 and a 52-week high of $16.45. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 8.83. The business’s 50-day moving average price is $11.67 and its 200-day moving average price is $6.92. The stock has a market capitalization of $318.12 million and a price-to-earnings ratio of -35.93.

Turn Therapeutics (NASDAQ:TTRX) last posted its earnings results on Wednesday, August 12th. The company reported ($0.20) EPS for the quarter. On average, research analysts expect that Turn Therapeutics will post -0.40 EPS for the current fiscal year.

Hedge Funds Weigh In On Turn Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. SteelPeak Wealth LLC lifted its position in shares of Turn Therapeutics by 0.7% during the 3rd quarter. SteelPeak Wealth LLC now owns 251,275 shares of the company’s stock valued at $3,616,000 after buying an additional 1,819 shares during the last quarter. TD Waterhouse Canada Inc. purchased a new stake in Turn Therapeutics in the 3rd quarter worth about $40,000. Jefferies Financial Group Inc. bought a new stake in Turn Therapeutics in the 2nd quarter valued at about $119,000. Bank of America Corp DE bought a new stake in Turn Therapeutics in the 2nd quarter valued at about $103,000. Finally, Ieq Capital LLC purchased a new stake in Turn Therapeutics during the second quarter valued at about $1,660,000.

Turn Therapeutics Company Profile

Turn Therapeutics, Inc is a biotechnology and pharmaceutical company focused on developing topical therapies for skin and wound-care applications. The company’s platform is designed to support the delivery of therapeutic compounds to the skin while helping address microbial contamination and other complications associated with wounds.

Turn Therapeutics has identified MVT-100 as a lead product candidate. The topical formulation is intended for use in wound-care settings, including the management of chronic and difficult-to-heal wounds.